Think we have to patient with Nearmap at the moment. It seems to have been beaten down a bit because it is a Tech Stock and as a group they are being hammered because of the recent vaccine breakthroughs. The market does not seem to be able to distinguish between those who will be affected and those who IMHO will not. Possibly this is because of Index Funds that lump them all together.
- Forums
- ASX - By Stock
- Ann: FY21 Annual Contract Value guidance